NEW YORK, March. 2, 2018 /PRNewswire/ -- WallStEquities.com strives to bring the best free research to the investment community. Today we are offeringreports on BLCM, BPMX, BLUE, and CALA which can be accessed for free by signing up to www.wallstequities.com/registration. Zacks reported that the US Biotech space has crushed the overall market and broader Healthcare sector so far this year. The
Houston, Texas headquartered Bellicum Pharmaceuticals Inc.'s stock finished Thursday's session 1.01% higher at $7.02 with a total trading volume of 677,867 shares. The stock is trading below their 50-day moving average by 8.64%. Shares of the Company, which focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the US and internationally, have a Relative Strength Index (RSI) of 51.45.
On February 21st, 2018, Bellicum Pharmaceuticals announced the appointment of Edmund Harrigan, M.D. to its Board of Directors. Dr. Harrigan has 28 years of Pharmaceutical industry experience, serving in various executive leadership positions across Business Development, Clinical, Drug Safety, and Regulatory affairs, most recently as Senior Vice President - Worldwide Safety and Regulatory at Pfizer Inc. Get the full research report on BLCM for free by clicking below at:
Shares in Menlo Park, California headquartered BioPharmX Corp. jumped 5.92%, ending yesterday's session at $0.27. A total volume of 27.63 million shares was traded, which was above their three months average volume of 9.90 million shares. The stock has skyrocketed 111.10% in the past month and 121.13% in the previous three months. The Company's shares are trading 90.80% above their 50-day moving average. Moreover, shares of BioPharmX, which develops and commercializes novel prescription and over-the-counter products that address dermatology and women's health market, have an RSI of 78.84. To experience our free membership services anytime/ anywhere and access the free report on BPMX, click to register at:
On Thursday, bluebird Cambridge, Massachusetts headquartered bio Inc.'s stock rose 1.07%, to close the day at $203.15. A total volume of 624,725 shares was traded. The Company's shares have advanced 22.05% in the previous three months and 118.91% over the past year. The stock is trading 6.56% and 46.56% above its 50-day and 200-day moving averages, respectively. Additionally, shares of bluebird bio, which focuses on developing transformative gene therapies for severe genetic diseases and cancer, have an RSI of 53.32.
On February 14th, 2018, bluebird bio appointed Alison Finger as Chief Commercial Officer. In this role, Alison will be responsible for shaping and delivering an integrated global commercial strategy to make the Company's gene therapies broadly accessible to patients. She will oversee all commercial strategy and operations, access management, including pricing, reimbursement and health outcomes, as well as patient operations.
On February 22nd, 2018, research firm Cantor Fitzgerald reiterated its 'Underweight' rating on the Company's stock with a decrease of the target price from $122 a share to $113 a share. Join our big investor community at Wall St. Equities today and get your free report on BLUE at:
Shares in South San Francisco, California headquartered Calithera Biosciences Inc. ended the day 0.65% higher at $7.75. A total volume of 474,850 shares was traded. The stock is trading below its 50-day moving average by 3.75%. Furthermore, shares of Calithera Biosciences, which focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the US, have an RSI of 49.50.
On February 16th, 2018, research firm Citigroup upgraded the Company's stock rating from 'Neutral' to 'Buy'. Know more about CALA in our free research coverage at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:Email: email@example.com Phone number: 21 32 044 483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/morning-technical-insight-on-these-biotech-stocks----bellicum-pharma-biopharmx-bluebird-bio-and-calithera-biosciences-300607309.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!
Complex regional pain syndrome (CRPS) is rare chronic pain disorder usually involving an arm or ...
Polyarthritis refers to pain in four or more joints simultaneously due to various causes ranging ...
Gardner or Gardner''s syndrome, also known as familial adenomatous polyposis (FAP), is an autosomal ...View All